BRIEF-BioVie says first patient dosed in trial for refractory ascites due to liver cirrhosis
September 28, 2017 at 07:15 AM EDT
* BioVie announces first patient dosed with BIV201 in Phase 2A clinical trial for refractory ascites due to liver cirrhosis Source text for Eikon: Further company coverage: